Florbetaben Amyloid Imaging for cognitive impairment in Parkinson’s disease
Degree GrantorUniversity of Canterbury
Degree NameMaster of Science
Objective: To determine using amyloid Positron Emission Tomographic (PET) imaging, whether amyloid burden indicated by Florbetaben (FBB) radiotracer, could predict cognitive decline in the Parkinson’s disease individuals with Mild cognitive impairment (PD-MCI). Methods: In study, movement disorder society (MDS) criteria were used to classify 50 participant with PD-MCI. All subjects underwent clinical evaluation, Structural 3T Magnetic resonance imaging and FBB PET imaging, along with cognitive assessments. The PET images were assessed clinically and the Standard uptake value ratio (SUVRs) were obtained for Region of interest (ROI) analysis, linear regression and multivariate analysis to asses association with cognitive and clinical measure. Results: At baseline, among the 50 scans, 22 % clinically FBB-positive. The Group-by- Cognition showed an association between amyloid deposition in regions: neocortical, frontal and temporal cortex, anterior and posterior cingulate, precuneus and putamen with the global cognitive Z score, MoCa and Parkinson’s disease dementia "risk" score (PDDRS). We also the pattern of amyloid accumulation in PD-MCI using multivariate analysis ( principal Component analysis). We showed an association between our principal components with the clinical classification of positivity and the neuropsychological score. PCs showed worsening of cognitive impairment in the clinically FBB positive group. In the context of FBB negative group there was no association with the cognitive decline. Conclusions: FBB-PET imaging allows in vivo visualization of amyloid deposition in PD-MCI. At baseline measurements, our study show that amyloid accumulation could potential contribute to cognitive deterioration in PD-MCI.